Physician profile
Yogesh Patel
NPI 1912944653
$5,979.01
in general payments reported to CMS, 2019-2025
29 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $631 · 2021: $842 · 2022: $1,072 · 2023: $1,056 · 2024: $698 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.66 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $880.64 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals Lp | $798.93 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $662.41 | 2019-2025 | Parsabiv, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $636.08 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $499.52 | 2019-2024 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $434.51 | 2019-2024 | Auryxia, Vafseo |
| Calliditas Therapeutics US INC. | $324.43 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $207.86 | 2023-2025 | |
| Medtronic, INC. | $194.90 | 2021-2024 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $182.54 | 2022-2023 | Intracept |
| Glaxosmithkline, LLC. | $179.92 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.85 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $126.36 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $99.83 | 2021-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $81.48 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $70.06 | 2025 | Empaveli |
| Horizon Therapeutics Plc | $63.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $63.35 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $58.00 | 2019-2023 | Velphoro |
| Ardelyx, INC. | $51.84 | 2023-2024 | Ibsrela |
| Scilex Pharmaceuticals INC. | $47.05 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.13 | 2022 | |
| Medtronic USA, INC. | $29.66 | 2019 | |
| Daiichi Sankyo INC. | $24.23 | 2024 | Injectafer |
| Bard Peripheral Vascular, INC. | $22.20 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.84 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.63 | 2025 | Ultomiris |
| Lilly USA, LLC | $18.41 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yogesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.